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A B S T R A C T
Objective: Non-adherence to antimicrobial guidelines in patients with bloodstream infection can result in un-
dertreatment, overtreatment, or equivalent treatment, and could lead to suboptimal care. Our aim was to ex-
amine the association between non-adherence and appropriate coverage as well as to assess the impact of non-
adherence on 30-day mortality.
Methods: We conducted a retrospective cohort study between 2012 and 2017 at a tertiary university hospital.
Adult patients attending the emergency department with a bloodstream infection were included. Adherence was
defined as guideline-recommended antibiotic therapy. Non-adherence was either undertreatment (too narrow-
spectrum), overtreatment (too broad-spectrum), or equivalent treatment. Outcomes were appropriate coverage
(i.e. antibiotic therapy that matches in vitro susceptibility of the isolated bacteria) and 30-day mortality.
Results: We included 909 patients of whom 395 (43.5%) were treated adherently, 355 (39.1%) were under-
treated, 87 (9.6%) were overtreated, and 72 (7.9%) received an equivalent treatment. Overtreated patients were
more severely ill, whilst undertreated patients had more favorable patient characteristics. Overtreatment did not
result in higher appropriate coverage, whereas undertreatment was associated with lower coverage (OR[95%CI]:
0.18 [0.12; 0.26]). Overtreatment and undertreatment were not associated with 30-day mortality.
Conclusions: Guideline adherence likely depends on disease severity, because overtreatment was more often
observed in patients with high disease severity and undertreatment in less severely ill patients. Undertreatment
was associated lower appropriate coverage but not with higher mortality. However, this can be the result of
residual confounding . Overtreatment did not result in higher appropriate antibiotic coverage nor a survival
benefit . Therefore, overtreatment seems not justifiable.
1. Introduction
1.1. Background
Bacterial infections can result in considerable mortality and have a
profound global burden [1–3]. Patients with a severe infection (e.g.
sepsis) often present in an acute care setting, such as the emergency
department (ED). To provide proper care in this setting, initiation of the
antibiotic therapy that matches in vitro susceptibility of the causative
bacteria (i.e. with appropriate coverage) is important [4]. However, the
causative pathogen has yet to be identified by cultures and this process
usually takes over 24 h. Therefore, antibiotic therapy in the ED is
virtually always initiated empirically [4].
1.2. Importance
For patients with a suspected bacterial infection, guideline re-
commendations for empiric antibiotic therapy should depend on local
prevalence of pathogens and antimicrobial resistance patterns [5]. Such
antimicrobial guidelines usually provide recommendations for a spe-
cific working diagnosis (i.e. suspected source of infection). The aim of
antimicrobial guidelines is to ensure that the antibiotic therapy with
appropriate coverage is given before culture results become available,
thereby preventing mortality. In addition, guidelines aim to reduce
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misuse of broad-spectrum antibiotic therapy, in order to prevent se-
lection of antimicrobial resistance and adverse effects [6].
1.3. Goal of this investigation
Non-adherence to antimicrobial guidelines in patients with a proven
bloodstream infection (BSI) is disadvantageous when it results in in-
appropriate coverage [7, 8]. Moreover, literature about non-adherence
in the ED is scarce and discrepant. Rate of non-adherence ranged from
10 to 53% and these studies did not differentiate between different
types of non-adherence (i.e. undertreatment, overtreatment, or
equivalent treatment) [9–11]. Therefore, we intended to evaluate non-
adherence to antimicrobial guidelines for adult patients with BSI at-
tending the ED. Our aims were primarily to examine the association
between the different types of non-adherence and appropriate cov-
erage, and secondly to assess the impact of non-adherence on 30-day
mortality.
2. Method
2.1. Study design and setting
We conducted a retrospective cohort study at the Erasmus
University Medical Center Rotterdam (Erasmus MC), which is a tertiary
university hospital in the Netherlands. We used data from all patients
attending the ED with BSI from July 2012 through December 2017. The
Medical Ethics Committee of the Erasmus MC reviewed this study and
concluded that it did not fall under the scope of the Medical Research
Involving Human Subjects Act and therefore no informed consent
needed to be obtained. This study is thus approved and registered under
MEC-2018-1744.
2.2. Selection of participants
Patients were eligible for inclusion if they were at least 18 years of
age, had a guideline-specified working diagnosis, and had a laboratory
proven bacterial BSI in the ED. BSI was defined as presence of a known
pathogen (e.g. E. coli) in one blood culture or a common commensal
(e.g. S. epidermidis) in at least two blood cultures collected on separate
occasions within two days from ED admission [12, 13]. Only the first
episode of BSI was included to prevent domination of results by in-
dividuals that frequently visited the ED.
2.3. Data collection and processing
Data were derived from an ED database and combined with a da-
tabase from Medical Microbiology, containing all collected blood cul-
tures [14]. The ED database included the working diagnosis, empiric
antibiotic therapy administered during the ED visit, other patient
characteristics, and mortality. General and demographic presenting
patients characteristics collected were: sex, age, arrival (by ambulance
or not), triage category (according to the Manchester Triage System)
[15], disposition (direct intensive care unit admittance or other), chills
[16], vomiting [16], need for vasopressors, and origin of infection
(nosocomial or community-acquired) [17]. To further account for in-
itial severity of disease we used the first recorded vital signs (i.e. body
temperature, heart rate, respiratory rate, systolic blood pressure,
oxygen saturation, and consciousness), whether there was need for any
supplemental oxygen, and calculated the National Early Warning Score
(NEWS) [18, 19] (Appendix A). Additionally, to account for co-
morbidity we collected all components of the age-adjusted Charlson
Comorbidity Index (CCI) [20] (Appendix B). For mortality data we used
municipal death registration records.
Patients with a positive blood culture in the ED were identified via
the blood culture database of Medical Microbiology [14]. This database
contained information about type of pathogen and its susceptibility
(antibiogram). Blood cultures were performed using the BACTEC
system (Becton Dickinson Diagnostic Instrument Systems, Sparks, Md)
according to the manufactures protocol. Type of pathogen was identi-
fied by MALDI-TOF MS analysis (Microflex, Bruker Daltonics, Bremen,
Germany). The in vitro susceptibility testing was performed using the
VITEK 2 (bioMérieux, Marcy l'Etoile, France) system. Based on earlier
applied antibiotic therapy in the ED and established in vitro suscept-
ibility of the isolated pathogen, we determined whether coverage of the
empiric therapy was appropriate or not. In accordance with previous
studies the following situations were scored as inappropriate coverage
of the isolated pathogen: no empiric antibiotic therapy, ineffective
antibiotic therapy (based on antibiogram or if dosage was lower than
guideline-recommended) or not intravenously administered antibiotic
therapy (except for antibiotics with high bioavailability such as cipro-
floxacin and metronidazole) [21].
Adherence to guidelines was defined as initial antibiotic therapy
administered in the ED in accordance with local hospital guideline re-
commendations for empiric antibiotic therapy [22]. This definition
corresponds to previous definitions of adherence in comparable study
settings [9–11]. Our empiric guideline recommendations depend on
national antimicrobial guidelines and are updated based on local pre-
valence and resistance patterns [23]. Guidelines provide re-
commendations for a specific working diagnosis, and are easily avail-
able online for all physicians in our hospital [22]. Guideline deviation
was considered adherent if a proper motivation was described in the
medical chart, i.e. if altered based on previous relevant cultures (only to
broaden therapy), and comorbidity (e.g. sickle cell disease, functional
asplenia). Additionally, empiric antibiotic therapy was considered ad-
herent if altered after direct consultation with a clinical microbiologist
or infectious diseases specialist, for example in case of renal disease (i.e.
applying an alternative to gentamicin while preserving the anti-
microbial spectrum if pre-existent glomerular filtration rate was <30
mL/min). In case of multiple working diagnoses, all highly suspected
diagnoses needed to be covered. Absence of antibiotic prescription was
considered adherent in case of a suspected cholecystitis (if not severely
ill and if not immunocompromised) and gastro-enteritis (if not recently
returned from traveling, without (persisting) high fever, no dysentery,
and if not immunocompromised). Over the study period there were
minor changes in hospital guidelines, which we took into account (see
table 1: primary meningitis).
Conversely, non-adherence was defined as failure to treat in ac-
cordance with the hospital guidelines. Previous studies did not divide
non-adherence into an undertreatment, overtreatment, and equivalent
group [9–11]. We scored non-adherence as undertreatment if therapy
was more narrow-spectrum than guideline-recommended therapy (e.g.
not administering antibiotics, omitting recommended gentamicin).
Overtreatment was scored if antibiotic therapy was more broad-spec-
trum than guideline-recommended therapy (e.g. administering addi-
tional antibiotic agents while not recommended). If antibiotic therapy
was non-adherent, but equivalent with regard to spectrum, a separate
equivalent group was introduced (e.g. amoxicillin/clavulanic acid with
gentamicin is equivalent to cefuroxime with gentamicin for cholangitis,
unknown sepsis, and urosepsis). Equivalent treatment was either in
accordance with national antimicrobial guidelines, or not. For a de-
tailed description of non-adherence scoring, see Appendix C.
The authors RS and AB independently reviewed all medical charts to
score both working diagnosis and whether the given antibiotic therapy
was adherent or not. In case of disagreement or doubt a meeting with
acute internists (JA, SKN) and medical microbiologists (JDS and AV)
was organized in which consensus was obtained.
2.4. Data analysis
We examined all presenting patient characteristics that reflect se-
verity of disease among adherently versus (vs.) non-adherently (i.e.
under-, over-, equivalently) treated patients. Based on distribution, data
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were compared using unpaired t-tests, chi-squared tests, or Fisher's
exact tests. Distribution of these patient characteristics should reveal
whether there are differences in initial disease severity between ad-
herently vs. non-adherently (i.e. under-, over-, equivalently) treated
patients.
First, we investigated the association between non-adherence and
appropriate antibiotic coverage with univariable logistic regression. We
did not control for patient characteristics because we assume they affect
appropriate antibiotic coverage only through (non)-adherence.
However, secondly, for the association between non-adherence and 30-
day mortality we did expect confounding by patient characteristics and
therefore we used multivariable logistic regression to limit bias. We
considered patient characteristics as confounders during further ana-
lyses if, based on expert knowledge, the characteristics were associated
with (non)-adherence and 30-day mortality [24]. Additionally, we re-
peated the analyses for two subgroups of undertreatment: (1) after
excluding patients that received no antibiotic therapy and (2) for pa-
tients in which gentamicin was omitted.
Results were presented as odds ratios (OR) with 95% confidence
intervals (CI). All hypothesis tests were 2-sided, with a significance
level of p< 0.05. We handled missing data using multiple imputations.
For efficiency purposes we imputed 20 datasets using the chained
equations method. Statistical analyses were performed using R version
3.6.3.
3. Results
3.1. Patient characteristics
We identified 1286 adult patients with a positive laboratory proven
blood culture taken in the ED. We excluded 247 patients with a re-
current BSI during our study period, resulting in 1039 unique patients
with BSI (Fig 1). 909 patients had a guideline-specified working diag-
nosis, which are shown in table 1. Most prevalent working diagnoses
among patients with BSI were urosepsis/pyelonephritis (n = 266,
29.3%) and cholangitis (n = 181, 19.9%). In 893 (98.2%) patients we
found a known pathogen (e.g. 311 Escherichia coli) and in 16 (1.8%) we
found a common commensal on multiple blood cultures collected on
separate occasions within two days from ED admission (e.g. 11 Sta-
phylococcus epidermidis). See appendix D for more detailed information
about the isolated bacteria. 30-day mortality was 11.4%.
Treatment was adherent for 395 (43.5%) patients, 355 (39.1%)
were undertreated, 87 (9.6%) were overtreated, and 72 (7.9%) received
equivalent treatment. Equivalently treated patients had therapy ac-
cording to national guidelines in 49 patients (68.1%). Overtreated pa-
tients received on average more than two antibiotics. Main reasons for
undertreatment were omitting recommended gentamicin (n = 217,
61.1%) and not administering antibiotics at all (n = 79, 22.3%). For a
detailed description, see Appendix C.
Table 1
Working diagnoses and guideline-recommended antibiotic therapy in patients with bloodstream infection at the emergency department.
Suspected infection focus Working diagnosis N (%) Subcategory Guideline-recommend antibiotic
therapy
Unknown Sepsis 98 (10.8) CA
HA
Cefuroxime and gentamicin
Piperacillin/tazobactam and
gentamicin
Febrile neutropenia Sepsis 37 (4.1) Meropenem
Urogenital Sepsis or pyelonephritis 266 (29.3) CA
HA
Cefuroxime and gentamicin
Piperacillin/tazobactam and
gentamicin
Respiratory Mild pneumonia (CURB 0–1) 45 (5.0) CA Amoxicillina
Moderate pneumonia
(CURB 2)
26 (2.9) CA Amoxicillin
Severe pneumonia (CURB
3–5)
37 (4.1) CA Amoxicillin/clavulanic acid and
ciprofloxacina
Pneumonia 25 (2.8) HA Piperacillin/tazobactam
(and gentamicin if doubt about source
or if septic)
Aspiration 9 (1.0) CA - Amoxicillin/clavulanic acida
- Cefuroxime and metronidazolea
Pulmonic abscess /pleura
empyema
9 (1.0) Amoxicillin/clavulanic acid
Abdominal Sepsis 29 (3.2) CA
HA
Cefuroxime and metronidazole and
gentamicin
Piperacillin/tazobactam and
gentamicin
Cholangitis 181 (19.9) Cefuroxime and gentamicin
Peritonitis, primary (SBP) 13 (1.4) Ceftriaxone
Peritonitis, secondary 11 (1.2) CA Cefuroxime and metronidazoleb and
gentamicin
Gastro-enteritis 18 (2.0) CA, returned from traveling; if (persisting) high fever,
dysentery, immunocompromised
Initially without antibiotic therapy
- Azithromycina
- Erythromycin and ciprofloxacin
Skin, soft tissue, bone Cellulitis 22 (2.4) Flucloxacillina
Erysipelas 14 (1.5) Penicillina
Central nervous system Meningitis, primary 32 (3.5) Before 2015: < 50 years, not immunocompromised Ceftriaxone and amoxicillin
Ceftriaxone
Intravascular, thorax Intravascular catheter 19 (2.1) - Vancomycin
- Cefuroxime and gentamicin
Only working diagnoses with a prevalence ≥1.0% are shown in this table.
Abbreviations: CA, community-acquired; HA, hospital-acquired; CURB65, confusion, blood urea nitrogen, respiratory rate, systolic blood pressure, age ≥ 65; SBP,
spontaneous bacterial peritonitis.
All antibiotic therapy had to be administered intravenously, except afor oral and bintraperitoneal administration was allowed.
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Undertreated patients had presenting characteristics that implied
lower disease severity compared to adherently treated patients: they
less frequently arrived by ambulance (16.6% vs. 30.1%), were less
likely in high triage categories (14.7% vs. 33.3%), and were less often
directly admitted to the intensive care unit (2.0% vs. 11.6%). In addi-
tion, undertreated patients had more normal vital signs and on average
a lower NEWS of 4 (± 3.1) vs. 6 (± 3.8). Especially, patients with
underlying mild liver disease and chronic kidney disease were more
often undertreated. Undertreated patients more often had a working
diagnosis of cholangitis, pyelonephritis, and urosepsis (Table 2). We
found that omitting recommended gentamicin was more prevalent in
patients with kidney disease (i.e. underlying chronic kidney disease
and/or a suspected pyelonephritis/urosepsis). See Appendix C.
Overtreated patients had presenting characteristics that implied
more critical illness than adherently treated patients. They were ap-
pointed to higher triage categories (52.4% vs. 33.3%) and had worse
vital signs. On average, overtreated patients had a higher NEWS of 8
(± 4.3) vs. 6 (± 3.8). Overtreatment more frequently occurred in
patients with underlying chronic pulmonary disease (25.3% vs. 12.2%).
Overtreated patients were more often diagnosed with mild- and mod-
erate community-acquired pneumonia (Table 2).
Equivalently treated patients had comparable presenting patient
characteristics to adherently treated patients and thus an equal initial
disease severity (NEWS of 6 (± 3.5) vs. 6 (± 3.8)). Only the number of
patients in high triage categories was lower for equivalently treated
patients (18.3% vs. 33.3%). Additionally, patients with underlying mild
liver disease and malignancies were more frequently present in the
equivalently treated group (Table 2).
3.2. Non-adherence and appropriate antibiotic coverage
Appropriate antibiotic coverage for the adherently treated was
89.1% (n = 352), for the undertreated 58.0% (n = 206), for the
overtreated 94.3% (n = 82), and for the equivalently treated 86.1%
(n = 62).
Undertreatment was associated with lower appropriate coverage
compared to adherent treatment (OR[95%CI]: 0.18 [0.12; 0.26]). After
excluding patients that received no antibiotic therapy, appropriate
coverage increased from 58.0% to 74.6%. However, undertreatment
remained associated with lower appropriate coverage (OR[95%CI]:
0.27 [0.16; 0.42]). Main reason for undertreatment was omitting gen-
tamicin. If in these patients gentamicin was not omitted appropriate
coverage would have increased from 72.8% to 91.7%. Which would be
comparable to coverage of adherent treatment (OR[95%CI]: 1.35 [0.76;
2.41], Table 3).
Overtreatment did not result in higher appropriate coverage com-
pared to adherent treatment (OR[95%CI]: 1.66 [0.77; 4.16]).
Equivalent treatment yielded equal appropriate coverage compared
to adherent treatment (OR[95%CI]: 0.86 [0.44; 1.82], Table 3).
3.3. Non-adherence and 30-day mortality
Crude 30-day mortality for the adherently treated was 11.9%
(n = 47), for the undertreated 9.9% (n = 35), for the overtreated
13.8% (n = 12), and for the equivalently treated 13.9% (n = 10).
There was no association between the three types of non-adherence and
30-day mortality after both crude estimation and multivariable ad-
justment (OR[95%CI] ranging from: 0.65 [0.28; 1.53] to 1.87 [0.79;
4.41], Table 4).
After excluding patients that received no antibiotic therapy, mor-
tality rate for undertreatment decreased from 9.9% to 9.1% and re-
mained not associated with mortality (OR[95%CI]: 0.93 [0.52; 1.89]).
Mortality rate was lower in undertreated patients in which gentamicin
was omitted (6.0%), however, not significantly different from adherent
treatment after adjustment for confounders (OR[95%CI]: 0.65 [0.29;
1.49]). Most patients that died in the gentamicin-omitted group re-
ceived antibiotic treatment with inappropriate coverage (n= 7), which
in 5 out of 7 patients would have been appropriate coverage if genta-
micin was not omitted (see Table 4).
4. Limitations
Our study has several limitations. First, we used retrospectively
collected data making our study prone to bias. However, the quality of
available data was assumed to be high as all data used was essential for
daily clinical practice. For only 13 patients (1.3%) documentation was
unclear on whether antibiotic therapy was administered in the ED or
after discharge, therefore we scored them as no (and thus in-
appropriate) antibiotic coverage.
Also, we want to emphasize that we only considered empiric
treatment in the ED, as this was our main study objective. Depending on
disease course and culture results, antibiotic therapy could have been
modified later on resulting in a different definitive antibiotic treatment.
Aside from empiric antibiotic treatment in the ED, this may have al-
tered survival as well.
5. Discussion
Our study aimed to evaluate non-adherence to antimicrobial
guidelines for adult patients with BSI attending the ED. Non-adherence
was high, and mainly the result of undertreatment. Non-adherence can
result in undertreatment, overtreatment, or equivalent treatment. As
these are potentially distinctive groups with respect to severity of dis-
ease and outcome, we analyzed them separately. Previous studies did
not differentiate between these different types of non-adherence
[9–11]. We found that, compared to adherently treated patients,
overtreated patients were more severely ill, whilst undertreated pa-
tients were less severely ill. As a result, guideline adherence likely de-
pends on clinical disease severity.
In the most severely ill patients, overtreatment may be a con-
sequence of a physicians’ intention to ensure appropriate antibiotic
Fig. 1. Flowchart of study selection.
Abbreviations: ED, emergency department, BSI, bloodstream infection.
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Table 2
Patient characteristics in adherently versus non-adherently (i.e. under-, over-, equivalently) treated patients .
Characteristic Adherence n = 395
(43.5)
Undertreatment n = 355
(39.1)
P value Overtreatment n = 87
(9.6)
P value Equivalent treatment
n = 72 (7.9)
P value
Sex, male 235 (59.5) 204 (57.5) .57 57 (65.5) .30 46 (63.9) .48
Age, mean (SD) 61.0 (16.3) 61.6 (14.8) .62 61.1 (14.4) .99 58.9 (15.9) .30
Arrival, by ambulance 119 (30.1) 59 (16.6) <0.001 30 (34.5) .43 19 (26.4) .49
Triage category, immediate/very
urgenta
122 (33.3) 50 (14.7) <0.001 44 (52.4) .001 13 (18.3) .01
Direct intensive care unit admittance 46 (11.6) 7 (2.0) <0.001 12 (13.8) .58 5 (6.9) .24
Chills 156 (39.5) 169 (47.6) .03 32 (36.8) .64 38 (52.8) .04
Vomiting 88 (22.3) 99 (27.9) .08 23 (26.4) .40 18 (25.0) .61
Need for vasopressors 24 (6.1) 5 (1.4) .001 10 (11.5) .07 1 (1.4) .10
Vital signs, mean (SD)
Body temperature, °Cb 38.4 (1.3) 38.2 (1.1) .08 38.4 (1.0) .59 38.4 (1.1) .99
Heart rate, /minc 109 (24.4) 102 (20.6) <0.001 117 (24.0) .007 109 (23.3) .98
Respiratory rate, /mind 24 (8.6) 22 (7.1) .003 27 (10.0) .01 22 (7.2) .11
Systolic blood pressure, mm Hge 124 (28.5) 127 (24.6) .08 120 (28.6) .23 125 (35.2) .77
Oxygen saturation,%f 95 (5.7) 96 (3.0) .02 93 (9.9) .07 96 (3.0) .58
Any supplemental oxygen 195 (49.4) 99 (27.9) <0.001 56 (64.4) .01 35 (48.6) .91
Consciousness, not alertg 64 (18.8) 19 (6.8) <0.001 19 (24.4) .26 8 (12.1) .20
NEWS, mean (SD)h 6 (3.8) 4 (3.1) <0.001 8 (4.3) .001 6 (3.5) .69
Comorbidities of the CCI
Diabetes mellitus, uncomplicated 72 (18.2) 74 (20.8) .37 14 (16.1) .64 18 (25.0) .18
Diabetes mellitus, end-organ damage 3 (0.8) 2 (0.6) .74 3 (3.4) .04 1 (1.4) .59
Liver disease, mild 32 (8.1) 69 (19.4) <0.001 7 (8.0) .99 18 (25.0) <0.001
Liver disease, moderate to severe 5 (1.3) 2 (0.6) .32 0 (0.0) .29 1 (1.4) .93
Malignancy, leukemia, lymphoma,
localized solid tumor
59 (14.9) 66 (18.6) .18 6 (6.9) .05 21 (29.2) .003
Malignancy, metastatic solid tumor 48 (12.2) 50 (14.1) .43 9 (10.3) .64 15 (20.8) .05
Chronic kidney disease 56 (14.2) 83 (23.4) .001 13 (14.9) .85 5 (6.9) .09
Chronic pulmonary disease 48 (12.2) 45 (12.7) .83 22 (25.3) .002 6 (8.3) .35
CCI, mean (SD) 4 (2.9) 5 (2.8) .02 4 (2.9) .84 5 (3.0) .11
Origin, hospital acquired 205 (51.9) 199 (56.1) .25 38 (43.7) .17 46 (63.9) .06
Ten most common working diagnoses
Cholangitis 25 (6.3) 115 (32.4) <0.001 5 (5.7) .84 36 (50.0) <0.001
Sepsis, urogenital 78 (19.7) 50 (14.1) .04 7 (8.0) .01 3 (4.2) .001
Pyelonephritis 33 (8.4) 94 (26.5) <0.001 1 (1.1) .02 0 (0.0) .01
Sepsis, unknown 59 (14.9) 25 (7.0) .001 10 (11.5) .41 4 (5.6) .03
Mild CA pneumonia (CURB 0–1) 12 (3.0) 7 (2.0) .35 20 (23.0) <0.001 6 (8.3) .03
Severe CA pneumonia (CURB 3–5) 18 (4.6) 14 (3.9) .68 4 (4.6) .99 1 (1.4) .21
Febrile neutropenia 32 (8.1) 2 (0.6) <0.001 1 (1.1) .02 2 (2.8) .11
Meningitis, primary 24 (6.1) 2 (0.6) <0.001 6 (6.9) .77 0 (0.0) .03
Sepsis, abdominal 15 (3.8) 12 (3.4) .76 0 (0.0) .07 2 (2.8) .67
Moderate CA pneumonia (CURB 2) 8 (2.0) 2 (0.6) .08 16 (18.4) <0.001 0 (0.0) .22
Data are presented as number (percentage) of patients unless otherwise indicated.
Missing data are not yet imputed.
Abbreviations: SD, standard deviation; NEWS, national early warning score; CCI, charlson comorbidity index [20]; CURB65, confusion, blood urea nitrogen, re-
spiratory rate, systolic blood pressure, age ≥ 65; CA, community-acquired..
a Data on triage category were missing for 44 (4.8%) patients.
b Data on body temperature were missing for 7 (0.8%) patients.
c Data on heart rate were missing for 18 (2.0%) patients.
d Data on respiratory rate were missing for 311 (34.2%) patients.
e Data on systolic blood pressure were missing for 14 (1.5%) patients.
f Data on oxygen saturation were missing for 39 (4.3%) patients.
g Data on consciousness were missing for 145 (16.0%) patients.
h NEWS imputed as normal.
Table 3
(Non-)adherence and appropriate antibiotic coverage.
Type of (non-)adherence Appropriate antibiotic coverage (%) Odds ratio 95% CI
Adherence (n = 395) 352 (89.1) 1.0 (reference)
Non-adherence:
Undertreatment (n = 355) 206 (58.0) 0.18 [0.12; 0.26]• No antibiotic therapy excluded (n = 276) 206 (74.6) 0.27 [0.16; 0.42]• Gentamicin was omitted (n = 217) 158 (72.8) 0.33 [0.21; 0.51]• If gentamicin would not have been omitted, i.e. adherence (n = 217)a 199 (91.7) 1.35 [0.76; 2.41]
Overtreatment (n = 87) 82 (94.3) 1.66 [0.77; 4.16]
Equivalent (n = 72) 62 (86.1) 0.86 [0.44; 1.82]
a This is a counterfactual group: these patients were not treated with recommended gentamicin, but we examined if coverage would have been appropriate if they
did receive gentamicin (i.e. if treatment would been adherent).
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coverage. However, our study shows that providing too broad-spectrum
antibiotic therapy is not justifiable, because overtreatment was not
associated with higher appropriate antibiotic coverage nor a survival
benefit. Furthermore, overtreatment in general leads to risk of selection
of antimicrobial resistance and adverse effects [6]. Therefore, ad-
herence to the guidelines should be preferred to provide proper care,
even when physicians encounter more severely ill patients. In ac-
cordance with previous studies, we found overtreatment was more
frequent in patients with underlying chronic pulmonary disease and a
suspected mild to moderate community-acquired pneumonia [25, 26].
Thus, for these patients with pulmonary disease, physicians should be
extra alert to potential overtreatment.
In less severely ill patients, physicians might decide to give no or
more narrow-spectrum antibiotic therapy than antimicrobial guidelines
would recommend. Undertreatment was the leading type of non-ad-
herence, thus, guidelines often advise more extensive treatment than
physicians in practice provide in less severely ill patients. For these
patients, clinical judgment of low disease severity potentially overruled
guideline recommendations. However, undertreatment resulted in
lower appropriate antibiotic coverage, also after excluding patients that
received no antibiotic therapy. Main reason for undertreatment was
omitting gentamicin. We found that if in these patients gentamicin was
not omitted, appropriate coverage would have been comparable to
coverage of adherent treatment. Undertreatment was not associated
with higher 30-day mortality. Although from our data there seems no
survival disadvantage for these less severely ill undertreated patients,
we have to emphasize that confounding by (low) severity of disease
could mask a survival disadvantage for undertreated patients. Thus,
finding no survival disadvantage in this case can be the result of re-
sidual confounding, which was also demonstrated in previous studies
[19]. Moreover, survival would have likely been better if these under-
treated patients with proven BSI did receive the antibiotic treatment
with appropriate coverage. Therefore, physicians should always be
cautious when they decide to undertreat and realize that appropriate
antibiotic coverage is significantly lower compared to guideline-ad-
herent therapy. We found undertreatment was more frequent in pa-
tients with underlying chronic kidney disease and a suspected pyelo-
nephritis/urosepsis. From literature and clinical practice this can be
explained by the intention to spare these patients from treatment with
nephrotoxic antibiotics such as gentamicin [27, 28]. In our data, we
found that omitting recommended gentamicin was more prevalent in
patients with kidney disease as well. However, as stated before, omit-
ting gentamicin affects appropriate coverage and therefore we would
argue that in these patients physicians should consult a medical mi-
crobiologist to find an alternative to gentamicin with comparable
coverage.
Non-adherence in our study (56.5%) was high compared to pre-
viously reported non-adherence rates (10 to 53%). However, previous
studies are likely underestimating the true non-adherence rate as they
excluded patients that received no antibiotic therapy [9–11]. Also, we
chose to score adherence very strictly to give an unbiased interpretation
of absolute guideline adherence. Strict scoring resulted in a few patients
that were non-adherent, but equivalently treated with regard to anti-
biotic spectrum. Equivalent treatment was frequently in accordance
with national antimicrobial guidelines. Equivalently treated patients
had comparable patient characteristics to adherently treated patients,
indicating comparable illness. As expected, equivalent treatment
yielded an equal rate of appropriate antibiotic coverage. Also, we found
no difference in 30-day mortality.
6. Conclusion
In patients with BSI attending the ED, the majority of antibiotic
therapy was non–adherent. Guideline adherence likely depends on
clinical disease severity. Undertreatment was the leading type of non-
adherence, mainly the result of omitting gentamicin, and most common
in less severely ill patients. Undertreatment was associated with lower
appropriate antibiotic coverage, but not with higher mortality.
Although we found no survival disadvantage, previous studies have
shown that this can be the result of residual confounding and survival
would have likely been better if these patients with proven BSI received
antibiotic therapy with appropriate coverage (i.e. guideline-adherent
treatment). Therefore, physicians should always be cautious when they
undertreat and realize that antibiotic coverage is significantly lower
compared to guideline-adherent therapy. Overtreatment was given to
the most severely ill patients and did not result in higher appropriate
antibiotic coverage nor a survival benefit. Together with the risk of
selection of antimicrobial resistance, overtreatment is not justifiable
even in case of high disease severity.
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gentamicin was not omitted.
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